The 2026 GLP-1 Weight Loss Trial Landscape

Q: Do GLP-1s reduce heart attacks and strokes?

SELECT studied semaglutide in more than 17,000 people who had overweight or obesity and established cardiovascular disease but did not have diabetes. Major adverse cardiac events fell from 8.0% on placebo to 6.5% on semaglutide — a 20% relative reduction. That population matters: it is the first outcome trial showing heart benefit in people taking a GLP-1 without diabetes. For tirzepatide, SURPASS-CVOT showed non-inferiority to dulaglutide in type 2 diabetes, and SURMOUNT-MMO is still running in obesity without diabetes.

Q: What are the open questions about muscle and maintenance?

Muscle loss — analyses suggest a significant share of weight lost is lean mass; protein and resistance training are the countermeasures. Regain after stopping — extension trials show most weight returns when the drug is stopped; maintenance is a discipline, not a given. Long-term safety — still being studied; most data is 1–2 years out.

A synthesis of the latest randomized controlled trials, real-world data, and the emerging evidence on muscle, metabolism, and maintenance.

Published September 12, 2026Updated September 15, 202614 min readWritten and fact-checked against the sources below

Read this first

Educational synthesis of published research, not medical advice. Trial averages are not individual predictions. Compounded GLP-1s are not FDA-approved, and since the 2025 shortage delistings they can only be dispensed in narrow, patient-specific circumstances.

The 2026 trial landscape for GLP-1s is richer than ever — cardiovascular outcomes, real-world data, and the muscle/maintenance questions. Here's a plain-language synthesis of what's actually been shown.

How much weight do GLP-1s cause people to lose in trials?

The headline results are stable: semaglutide (Wegovy®) around 15% average loss, tirzepatide (Zepbound®) around 20–22%, and the triple agonist retatrutide reporting 28.3% at 80 weeks in its pivotal Phase 3 trial, TRIUMPH-1. These are trial averages under close monitoring — not what to expect individually.

Do GLP-1s reduce heart attacks and strokes?

SELECT studied semaglutide in more than 17,000 people who had overweight or obesity and established cardiovascular disease but did not have diabetes. Major adverse cardiac events fell from 8.0% on placebo to 6.5% on semaglutide — a 20% relative reduction. That population matters: it is the first outcome trial showing heart benefit in people taking a GLP-1 without diabetes. For tirzepatide, SURPASS-CVOT showed non-inferiority to dulaglutide in type 2 diabetes, and SURMOUNT-MMO is still running in obesity without diabetes.

What are the open questions about muscle and maintenance?

Muscle loss — analyses suggest a significant share of weight lost is lean mass; protein and resistance training are the countermeasures.
Regain after stopping — extension trials show most weight returns when the drug is stopped; maintenance is a discipline, not a given.
Long-term safety — still being studied; most data is 1–2 years out.

What is still uncertain about GLP-1s in 2026?

How much of the cardiovascular benefit extends to people at lower baseline cardiac risk than the SELECT population.
The long-term muscle and metabolic trajectory.
Whether and how to taper versus continue indefinitely.

Bottom line

The 2026 evidence base is strong on weight loss and increasingly on cardiovascular benefit, with open questions on muscle, maintenance, and long-term safety. Trial averages are not individual predictions. This is an educational synthesis, not medical advice.

Want this handled for you?

LunaRx — clinician-led GLP-1 care with a plan to come off

LunaRx connects you with a licensed clinician for an online evaluation. Depending on your state that is a live or a store-and-forward visit. If the clinician determines a GLP-1 is appropriate for you, a licensed pharmacy dispenses it — with a plan to come off when you’re ready. The prescribing decision is the clinician’s alone, and approval is not guaranteed.

Start the 2-minute eligibility checkIndependent site · by LunaRx · not medical advice

Sources

Primary sources for the claims in this article. Trial results are reported as published; prescribing information is the authoritative reference for dosing and safety.

1.
STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, et al. · New England Journal of Medicine · 2021
Mean weight change of −14.9% with semaglutide 2.4 mg versus −2.4% with placebo at 68 weeks.
2.
SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, et al. · New England Journal of Medicine · 2022
Mean weight change of −20.9% on tirzepatide 15 mg at 72 weeks, in 2,539 adults without diabetes.
3.
TRIUMPH-1: Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
Eli Lilly and Company (sponsor release) · 2026
At 80 weeks in 2,339 adults: −19.0% (4 mg), −25.9% (9 mg), −28.3% (12 mg) versus −2.2% placebo.
4.
SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff AM, et al. · New England Journal of Medicine · 2023
20% relative reduction in major adverse cardiovascular events (8.0% to 6.5% absolute) with semaglutide 2.4 mg.
5.
STEP 1 DXA substudy: Once-Weekly Semaglutide in Adults with Overweight or Obesity — body-composition substudy (DXA, n=140)
Wilding JPH, et al. · Exploratory analysis reported within STEP 1 · 2021
Of 13.6 kg mean weight lost, 5.26 kg was lean body mass and 8.36 kg was fat mass — lean tissue was about 39% of the total. Note that lean-mass findings across the wider literature are mixed; this substudy sits at the higher end.

Get the weekly research update

New trials, FDA moves, and pricing shifts — one plain-English email a week. No spam.

Unsubscribe anytime. Read our privacy policy.